Clinical trials referenced in this document:
Documents that mention this clinical trial
Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Ocedurenone (KBP-5074) in Individuals with Moderate Hepatic Impairment
https://doi.org/10.1007/s13318-024-00879-3
Funding for this research was provided by:
KBP BioSciences Co., Ltd.
Article History
Accepted: 17 January 2024
First Online: 8 February 2024
Declarations
:
: Funding for this study and manuscript was provided by KBP BioSciences USA, Inc., Princeton, NJ, USA.
: Authors were employees of KBP Biosciences USA, Inc., Princeton, NJ, but have no other relevant financial or non-financial interests to disclose.
: Data and materials information can be made available upon reasonable request.
: Not applicable.
: Not applicable.
: Before the start of the study, the protocol, informed consent form, investigator’s brochure, and other relevant documents were reviewed and approved by the appropriate Institutional Review Board. The study was conducted in accordance with the protocol and with the consensus ethical principles derived from international guidelines, including the Declaration of Helsinki [CitationRef removed], the Council for International Organizations of Medical Sciences [CitationRef removed], and the International Conference on Harmonization Good Clinical Practice Guideline [CitationRef removed], as well as applicable laws and regulations.
: All subjects provided informed consent before participation in this study.
: Jay Zhang, James McCabe, and Fred Yang participated in the research design. Jay Zhang and James McCabe performed data analysis. James McCabe, Vincent Benn, Fred Yang, and Jay Zhang wrote or contributed to the writing of the manuscript. James McCabe provided medical oversight. All authors read and approved the final manuscript.